Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Pathology of Hepatobiliary Diseases
share announcement

Pathology of Hepatobiliary Diseases

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 5483

Special Issue Editors

Dr. Mukul Vij

E-Mail Website
Guest Editor
Department of Pathology, Dr. Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India
Interests: hepatopathology; primary liver cancer; pediatric cholestasis; anatomic pathology; transplant pathology
Dr. Julien Calderaro

E-Mail Website
Guest Editor
Département de Pathologie, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
Interests: hepatopathology; primary liver cancer; artificial intelligence in liver diseases; molecular liver pathology

Special Issue Information

Dear Colleagues,

Hepatobiliary diseases are a highly complex and heterogeneous group of disorders that include a vast number of benign and malignant conditions. There has been a worldwide increase in the number of patients afflicted with hepatobiliary diseases. Light microscopic evaluation remains the gold standard for the diagnosis of most pediatric and adult primary hepatobiliary diseases, as well as focal or diffuse space-occupying lesions. These are very exciting times in liver pathology, as there has been tremendous improvement in our understanding of the pathogenetic process of many hepatobiliary disease processes and liver cancer, thus, further strengthening the role of pathologists evaluating liver biopsies.

This Special Issue aims to review advances in the pathology of pediatric and adult hepatobiliary diseases, such as cholestasis, steatohepatitis, autoimmune hepatitis, cholangiopathies, vascular liver diseases, drug-induced liver injury, primary liver cancer and others. We welcome original submissions, reviews, or brief reports for this Special Issue.

Dr. Mukul Vij
Dr. Julien Calderaro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • primary liver cancer
  • cholestasis
  • hereditary liver diseases
  • hepatitis
  • cholangiopathy
  • steatohepatitis
  • allograft pathology
  • molecular pathology
  • drug-induced liver injury
  • pediatric liver tumors

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 558 KiB  
Article
Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature
by Manon N. G. J. A. Braat, Sander C. Ebbers, Ahmed A. Alsultan, Atal O. Neek, Rutger C. G. Bruijnen, Maarten L. J. Smits, Joep de Bruijne, Marnix G. E. H. Lam and Arthur J. A. T. Braat
Diagnostics 2023, 13(24), 3652; https://doi.org/10.3390/diagnostics13243652 - 12 Dec 2023
Viewed by 889
Abstract
Purpose: Trans-arterial radioembolization is a well-studied tumoricidal treatment for liver malignancies; however, consensus and evidence regarding periprocedural prophylactic medication (PPM) are lacking. Methods: A single-center retrospective analysis from 2014 to 2020 was performed in patients treated with 90Y-glass microspheres for neuroendocrine or [...] Read more.
Purpose: Trans-arterial radioembolization is a well-studied tumoricidal treatment for liver malignancies; however, consensus and evidence regarding periprocedural prophylactic medication (PPM) are lacking. Methods: A single-center retrospective analysis from 2014 to 2020 was performed in patients treated with 90Y-glass microspheres for neuroendocrine or colorectal liver metastases. Inclusion criteria were the availability of at least 3 months of clinical, biochemical, and imaging follow-up and post-treatment 90Y-PET/CT imaging for the determination of the whole non-tumorous liver absorbed dose (Dh). Logistic regression models were used to investigate if variables (among which are P/UDCA and Dh) were associated with either clinical toxicity, biochemical toxicity, or hepatotoxicity. Additionally, a structured literature search was performed in November 2022 to identify all publications related to PPM use in radioembolization treatments. Results: Fifty-one patients received P/UDCA as post-treatment medication, while 19 did not. No correlation was found between toxicity and P/UDCA use. Dh was associated with biochemical toxicity (p = 0.05). A literature review resulted in eight relevant articles, including a total of 534 patients, in which no consistent advice regarding PPM was provided. Conclusion: In this single-center, retrospective review, P/UDCA use did not reduce liver toxicity in patients with metastatic liver disease. The whole non-tumorous liver-absorbed dose was the only significant factor for hepatotoxicity. No standardized international guidelines or supporting evidence exist for PPM in radioembolization. Full article
(This article belongs to the Special Issue Pathology of Hepatobiliary Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

16 pages, 40726 KiB  
Review
Autoimmune Hepatitis: From Evolution to Current Status—A Pathologist’s Perspective
by Puja Sakhuja and Surbhi Goyal
Diagnostics 2024, 14(2), 210; https://doi.org/10.3390/diagnostics14020210 - 18 Jan 2024
Viewed by 1008
Abstract
Autoimmune hepatitis (AIH) is a chronic, relapsing and remitting, immune-mediated liver disease that progresses to cirrhosis if left untreated. A significant number of patients may present with acute hepatitis or acute liver failure, which are often misdiagnosed as toxic liver injury. AIH shows [...] Read more.
Autoimmune hepatitis (AIH) is a chronic, relapsing and remitting, immune-mediated liver disease that progresses to cirrhosis if left untreated. A significant number of patients may present with acute hepatitis or acute liver failure, which are often misdiagnosed as toxic liver injury. AIH shows a preponderance in young women but may be seen in children and the elderly. Diagnosis requires the integration of clinical, biochemical, and serologic parameters, along with supportive liver histology and exclusion of other causes of liver disease. Liver biopsy is a prerequisite for diagnosis of AIH, to assess severity and stage of disease, exclude other entities, and recognize any concurrent morbidities. No single biomarker or histologic feature is pathognomonic for AIH. The diagnostic and histologic criteria have undergone several modifications since the original scoring system was proposed by the International Autoimmune Hepatitis Group (IAIHG) in 1993. Recently, the IAIHG has proposed consensus recommendations for histologic criteria, relevant for both acute and chronic AIH. This review article will describe the evolving diagnostic criteria for AIH, with their limitations and utility, and with an emphasis on the role of liver histology in the diagnosis and management of AIH. Full article
(This article belongs to the Special Issue Pathology of Hepatobiliary Diseases)
►▼ Show Figures

Figure 1

58 pages, 76598 KiB  
Review
Update on the Pathology of Pediatric Liver Tumors: A Pictorial Review
by Priyanka Bhagat, Mukul Vij, Lexmi Priya Raju, Gowripriya Gowrishankar, Jagadeesh Menon, Naresh Shanmugam, Ilankumaran Kaliamoorthy, Ashwin Rammohan and Mohamed Rela
Diagnostics 2023, 13(23), 3524; https://doi.org/10.3390/diagnostics13233524 - 24 Nov 2023
Cited by 1 | Viewed by 2102
Abstract
Liver tumors in children are uncommon and show remarkable morphologic heterogeneity. Pediatric tumors may arise from either the epithelial or mesenchymal component of the liver and rarely may also show both lines of differentiation. Both benign and malignant liver tumors have been reported [...] Read more.
Liver tumors in children are uncommon and show remarkable morphologic heterogeneity. Pediatric tumors may arise from either the epithelial or mesenchymal component of the liver and rarely may also show both lines of differentiation. Both benign and malignant liver tumors have been reported in children. The most common pediatric liver tumors by age are benign hepatic infantile hemangiomas in neonates and infants, malignant hepatoblastoma in infants and toddlers, and malignant hepatocellular carcinoma in teenagers. Here, we provide an up-to-date review of pediatric liver tumors. We discuss the clinical presentation, imaging findings, pathology, and relevant molecular features that can help in the correct identification of these tumors, which is important in managing these children. Full article
(This article belongs to the Special Issue Pathology of Hepatobiliary Diseases)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

6 pages, 4885 KiB  
Interesting Images
Aggressive Variant of Hepatic Epstein–Barr Virus-Associated Inflammatory Pseudotumor-like Follicular Dendritic Cell Sarcoma with PD-L1 and SSTR2a Expression
by Madhur Pardasani, Muthukumarassamy Rajakannu, Mukul Vij, Rajesh Rajalingam and Mohamed Rela
Diagnostics 2023, 13(18), 2916; https://doi.org/10.3390/diagnostics13182916 - 12 Sep 2023
Viewed by 998
Abstract
An aggressive Epstein–Barr virus (EBV)-associated inflammatory pseudotumor-like follicular dendritic cell (IPT-like FDC) sarcoma is reported in an adult female. The patient developed multifocal recurrence and passed away 13 months after the initial surgical resection. A bright field microscopic examination of the tumor demonstrated [...] Read more.
An aggressive Epstein–Barr virus (EBV)-associated inflammatory pseudotumor-like follicular dendritic cell (IPT-like FDC) sarcoma is reported in an adult female. The patient developed multifocal recurrence and passed away 13 months after the initial surgical resection. A bright field microscopic examination of the tumor demonstrated a classical growth pattern and the diffuse expression of Programmed death ligand 1 (PD-L1) and somatostatin receptor 2a (SSTR2a). Full article
(This article belongs to the Special Issue Pathology of Hepatobiliary Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop